2021 FDA kwadoro ọgwụ ọhụrụ 1Q-3Q

Ihe ọhụrụ na-akwalite ọganihu.Mgbe a bịara n'ihe ọhụrụ na mmepe nke ọgwụ ọhụrụ na ngwaahịa ọgwụgwọ ọgwụgwọ, FDA's Center for Drug Evaluation and Research (CDER) na-akwado ụlọ ọrụ ọgwụ na usoro ọ bụla.N'iji nghọta ya banyere sayensị na-emepụta ngwaahịa ọhụrụ, nyocha na usoro mmepụta ihe, yana ọrịa na ọnọdụ ndị a na-emepụta na ngwaahịa ọhụrụ, CDER na-enye ndụmọdụ sayensị na usoro iwu chọrọ iji weta ọgwụgwọ ọhụrụ n'ahịa.
Ịnweta ọgwụ ọhụrụ na ngwaahịa ndị dị ndụ na-apụtakarị nhọrọ ọgwụgwọ ọhụrụ maka ndị ọrịa na ọganihu na nlekọta ahụike maka ọha America.N'ihi nke a, CDER na-akwado ihe ọhụrụ ma na-arụ ọrụ dị mkpa n'inyere aka ịkwalite mmepe ọgwụ ọhụrụ.
Kwa afọ, CDER na-akwado ọtụtụ ọgwụ ọhụrụ na ngwaahịa ndị dị ndụ:
1. Ụfọdụ n'ime ngwaahịa ndị a bụ ngwaahịa ọhụrụ na-emepụta ihe ọhụrụ nke a na-ejikarị eme ihe na ụlọ ọgwụ.N'okpuru ebe a bụ ndepụta nke ụlọ ọrụ molecular ọhụrụ yana ngwaahịa ọgwụgwọ ọhụrụ nke CDER kwadoro na 2021. Ndepụta a enweghị ọgwụ mgbochi, ngwaahịa allergenic, ngwaahịa ọbara na ọbara, ihe ndị na-emepụta plasma, ngwaahịa cellular na genetherapy, ma ọ bụ ngwaahịa ndị ọzọ kwadoro na 2021 site n'aka. Center for Biologics Evaluation and Research.
2. Ndị ọzọ bụ otu ihe, ma ọ bụ metụtara ngwaahịa akwadoro na mbụ, na ha ga-asọmpi na ngwaahịa ndị ahụ n'ahịa.Hụ Drugs@FDA maka ozi gbasara ọgwụ niile CDER kwadoro na ngwaahịa ndu.
A na-ekewa ụfọdụ ọgwụ dị ka ihe ọhụrụ molekụla ("NME") maka ebumnuche nke nyocha FDA.Ọtụtụ n'ime ngwaahịa ndị a nwere ihe ndị na-arụ ọrụ nke FDA na-akwadobughị, ma ọ bụ dịka otu ọgwụ ma ọ bụ dịka akụkụ nke ngwaahịa ngwakọta;ngwaahịa ndị a na-enyekarị ọgwụgwọ ọhụrụ dị mkpa maka ndị ọrịa.A na-eji ụfọdụ ọgwụ eme ihe dị ka NME maka ebumnuche nhazi, mana n'agbanyeghị nke ahụ nwere akụkụ ndị na-arụ ọrụ nke nwere njikọ chiri anya na ihe ndị na-arụ ọrụ na ngwaahịa ndị FDA kwadoro na mbụ.Dịka ọmụmaatụ, CDER na-ekewa ngwaahịa ndị dị ndụ edobere na ngwa n'okpuru ngalaba 351 (a) nke Iwu Ọrụ Ahụike Ọha dịka NMEs maka ebumnuche nyocha FDA, n'agbanyeghị ma Agencylọ ọrụ ahụ akwadobula ihe arụrụ arụ ọrụ na ngwaahịa dị iche.Nhazi FDA nke ọgwụ dị ka "NME" maka ebumnuche nyocha dị iche na mkpebi FDA maka ma ngwaahịa ọgwụ ọ bụ "ihe ọhụrụ kemịkal" ma ọ bụ "NCE" n'ime ihe Federal Food, Drug, and Cosmetic Act pụtara.

Mba. Aha ọgwụ Ihe na-arụ ọrụ Ụbọchị nkwado FDA kwadoro iji na ụbọchị nkwado*
37 Exkivity mobocertinib 9/15/2021 Iji gwọọ ọrịa cancer akpa ume na-abụghị obere cell nke mpaghara ma ọ bụ metastatic na mmụgharị ntinye ntinye nke exon 20.
36 Skytrofa lonapegsomatropin-tcgd 8/25/2021 Iji na-emeso mkpụmkpụ ogologo n'ihi ezughị ezu secretion nke endogenous uto hormone
35 Korsuva dị njikere 8/23/2021 Iji gwọọ ọzịza na-agafeghị oke na nke siri ike metụtara ọrịa akụrụ na-adịghị ala ala na ụfọdụ ndị mmadụ
34 Welireg belzutifan 8/13/2021 Iji gwọọ ọrịa von Hippel-Lindau n'okpuru ọnọdụ ụfọdụ
33 Nexviazyme avalglucosidase alfa-ngpt 8/6/2021 Iji gwọọ ọrịa Pompe n'oge mmalite
Mbipụta ndị nchụ nta akụkọ
32 Saphnelo anifrolumab-fnia 7/30/2021 Iji gwọọ lupus erythematusus sistemu dị oke oke ruo oke yana usoro ọgwụgwọ ọkọlọtọ
31 Bylvay odevixibat 7/20/2021 Iji gwọọ itching
30 Rezurock belumosudil 7/16/2021 Iji gwọọ ọrịa na-adịghị ala ala graft-versus-host mgbe ọdịda nke opekata mpe ahịrị abụọ tupu usoro ọgwụgwọ
29 fexinidazole fexinidazole 7/16/2021 Iji gwọọ trypanosomiasis ụmụ mmadụ Africa kpatara site na parasaiti Trypanosoma brucei gambiense
28 Kerendia finerenone 7/9/2021 Iji belata ihe ize ndụ nke akụrụ na obi mgbagha na ọrịa akụrụ na-adịghị ala ala jikọtara ya na ụdị ọrịa shuga 2
27 Rylaze asparaginase erwinia chrysanthemi (recombinant) -rywn 6/30/2021 Iji gwọọ nnukwu ọrịa leukemia lymphoblastic na lymphoblastic lymphoma na ndị ọrịa nwere ihe nfụkasị na ngwaahịa asparaginase sitere na E. coli, dịka akụkụ nke usoro ọgwụgwọ chemotherapy.
Mbipụta ndị nchụ nta akụkọ
26 Aduhelm aducanumab-avwa 6/7/2021 Iji gwọọ ọrịa Alzheimer
Mbipụta ndị nchụ nta akụkọ
25 Brexafemme ibéxafungerp 6/1/2021 Iji gwọọ vulvovaginal candidiasis
24 Lybalvi olanzapine na samidorphan 5/28/2021 Iji gwọọ schizophrenia na akụkụ ụfọdụ nke ọrịa bipolar I
23 Truseltik infigratinib 5/28/2021 Iji gwọọ cholangiocarcinoma nke ọrịa ya na-emezu ihe ụfọdụ
22 Lumakras sotorasib 5/28/2021 Iji gwọọ ụdị ọrịa kansa akpa ume na-abụghị obere cell
Mbipụta ndị nchụ nta akụkọ
21 Pylarify piflufolastat F18 5/26/2021 Iji chọpụta ọnya antigen-prostate kpọmkwem akpụkpọ ahụ na ọrịa kansa prostate
20 Rybrevant amivantamab-vmjw 5/21/2021 Iji gwọọ akụkụ nke ọrịa kansa akpa ume na-abụghị obere cell
Mbipụta ndị nchụ nta akụkọ
19 Empaveli pegcetacoplan 5/14/2021 Maka ọgwụgwọ paroxysmal nocturnal hemoglobinuria
18 Zynlonta loncastuximab tesirine-lpyl 4/23/2021 Iji gwọọ ụfọdụ ụdị nlọghachi azụ ma ọ bụ refractory nnukwu B-cell lymphoma
17 Jemperli dostarlimab-gxly 4/22/2021 Maka ọgwụgwọ ọrịa cancer endometrial
Mbipụta ndị nchụ nta akụkọ
16 Nextstellis drospirenone na estetrol 4/15/2021 Iji gbochie afọ ime
15 Qelbree Viloxazine 4/2/2021 Iji gwọọ nsogbu nlebara anya hyperactivity
14 Zegalogue dasiglucagon 3/22/2021 Iji gwọọ hypoglycemia siri ike
13 Ponvory ponesimod 3/18/2021 Iji gwọọ ụdị nlọghachi azụ nke otutu sclerosis
12 Fotivda tivozanib 3/10/2021 Iji gwọ ọrịa carcinoma gbasara akụrụ
11 Azstarys Serdexmethylphenidate na 3/2/2021 Iji gwọọ nsogbu nlebara anya hyperactivity
dexmethylphenidate
10 Pepaxto melphalan flufenamide 2/26/2021 Iji gwọọ ọtụtụ myeloma nlọghachi azụ ma ọ bụ refractory
9 Nulibry fosdenopterin 2/26/2021 Iji belata ihe ize ndụ nke ịnwụ na ụkọ molybdenum cofactor Type A
Mbipụta ndị nchụ nta akụkọ
8 Amondys 45 casimersen 2/25/2021 Iji na-emeso Duchenne muscular dystrophy
Mbipụta ndị nchụ nta akụkọ
7 Cosela trilacicilib 2/12/2021 Iji belata chemotherapy-ebutere myelosuppression na obere mkpụrụ ndụ kansa akpa ume
Mbipụta ndị nchụ nta akụkọ
6 Evkeeza evinacumab-dgnb 2/11/2021 Iji gwọọ hypercholesterolemia homozygous familial
5 Ukoniq umbralisib 2/5/2021 Iji na-emeso akụkụ akụkụ nke lymphoma na follicular lymphoma
4 Tepmetko tepotinib 2/3/2021 Iji gwọọ ọrịa kansa akpa ume na-abụghị obere cell
3 Lupkynis Voclosporin 1/22/2021 Iji gwọọ lupus nephritis
Nleta onyonyo nke ọgwụ
2 Cabenuva cabotegravir na rilpivirine (nchịkọta ọnụ) 1/21/2021 Iji gwọọ nje HIV
Mbipụta ndị nchụ nta akụkọ
Nleta onyonyo nke ọgwụ
1 Verquvo vericiguat 1/19/2021 Iji belata ihe ize ndụ nke ọnwụ obi na ụlọ ọgwụ maka ọdịda obi na-adịghị ala ala
Nleta onyonyo nke ọgwụ

 

Edepụtara "FDA-akwadoro ojiji" na webụsaịtị a bụ naanị maka ebumnuche ngosi.Iji hụ ọnọdụ ojiji FDA kwadoro (dịka ọmụmaatụ, egosi(s), ọnụ ọgụgụ(s), usoro doses) maka ngwaahịa ndị a nke ọ bụla, hụ Ozi Ntuziaka Ntuziaka FDA kwadoro na nso nso a.
Kpọtụrụ na weebụsaịtị FDA:https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021


Oge nzipu: Sep-27-2021